A5053302756- Ovarian cancer diagnosis and treatment
- Endometriosis Research and Treatment
- Uterine Myomas and Treatments
- Endometrial and Cervical Cancer Treatments
- Pelvic floor disorders treatments
- Intraperitoneal and Appendiceal Malignancies
- Anorectal Disease Treatments and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Breast Lesions and Carcinomas
- Breast Cancer Treatment Studies
- Enhanced Recovery After Surgery
- Breast Implant and Reconstruction
- Urinary Tract Infections Management
- Gynecological conditions and treatments
- Reconstructive Surgery and Microvascular Techniques
- Ovarian function and disorders
- Reproductive Biology and Fertility
- Pelvic and Acetabular Injuries
- Hernia repair and management
- Genetic factors in colorectal cancer
- Cancer and Skin Lesions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Anesthesia and Pain Management
- Maternal and fetal healthcare
- Cancer, Lipids, and Metabolism
Université de Caen Normandie
2014-2024
Centre Hospitalier Universitaire de Caen
2014-2024
Inserm
2013-2024
Normandie Université
2019-2024
Cancers et Préventions
2019-2024
Centre François Baclesse
2022-2023
Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers
2020-2023
Hôpital Femme Mère Enfant
2020
Centre Hospitalier Universitaire Amiens-Picardie
2007-2016
Université de Picardie Jules Verne
2011-2014
AimTo investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma.MethodsMulticentre, open-label, non-comparative phase II study. Ninety-five randomised (2:1) receive four cycles CP ±3 concomitant 15 mg/kg...
BackgroundThe discovery of a saliva-based micro–ribonucleic acid (miRNA) signature for endometriosis in 2022 opened up new perspectives early and noninvasive diagnosis the disease. The 109-miRNA saliva is product miRNA biomarkers artificial intelligence (AI) modeling. We designed multicenter study to provide external validation its diagnostic accuracy. present here an interim analysis.MethodsThe first 200 patients included prospective ENDOmiRNA Saliva Test (NCT05244668) were analysis....
Abstract BACKGROUND The purpose of the current study was to examine surgical management women with borderline ovarian tumors and adequacy initial staging according guidelines International Federation Gynecology Obstetrics; evaluate impact restaging operations; identify risk factors for understaging. METHODS In a retrospective French multicenter study, 54 360 underwent operation. After excluding complete ( n = 62), epidemiologic, surgical, histologic parameters recurrence were compared...
The borderline ovarian Brenner tumor (BOBT) of the ovary is a rare tumor, and fewer than 25 cases have been reported in literature. aim this study was to determine prognosis series BOBT collected 2 reference centers.A retrospective review patients with treated or referred our institutions. A centralized histological by pathologist data on clinical characteristics, management, outcomes were required for inclusion.Ten identified between 2000 2010. median age 69 years (range, 52-84 years)....
Here we report the outcomes of 26 patients who relapsed following conservative surgical treatment stage I serous borderline ovarian tumours treated initially with fertility-sparing surgery. All recurrences were diagnosed by systematic ultrasonography during follow-up. Eleven at least twice after such management. Twenty-one pregnancies observed in 13 patients. these became pregnant their first recurrence. had a tumour and/or non-invasive peritoneal implants time recurrence but two them...